A significant fraction of the biopharma pipeline is held by small – and even virtual – biopharma companies. These companies often lack the all of the capabilities, expertise and/or bandwidth necessary to advance their molecules to initial clinical studies. In the absence of internal resources, small biopharma often look to contract development and manufacturing organizations (CDMOs) to support their development programs. While it is common to support these activities through consultants and multiple CDMOs, studies indicate that working with a single integrated service provider for API and drug product can reduce complexity, development timelines, and costs.
Please join Biocom California and Lonza for a half day virtual symposium as we discuss capabilities across critical aspects of rapidly advancing today’s molecules.
The role of solid form selection services within API development
Particle engineering considerations to improve bioavailability
Phase-appropriate and scalable drug product development for first-in-human studies